- Email: [email protected]
New perspectives on blood components preparation, quality, safety and review of non-viral transfusion complications
Transfusion and Apheresis Science 29 (2003) 3–4 www.elsevier.com/locate/transci
International forum: UK––Part 1
New perspectives on blood components preparation, quality, safety and review of non-viral transfusion complications
The issue of quality improvement of blood components continues to attract much attention from transfusion specialists and clinicians. This is understandable as despite the conceptual acceptance that purer is better and the implementation of this concept to blood component therapy, the potential risk of non-viral adverse reactions is still too high. It is therefore crucial to carefully assess the benefits and shortcomings attributable to various existing blood component technologies, in particular the universal leucodepletion program and put in place continual interventional programs with the aim of improving the safety/efficacy of various products for clinical use. The major goal of this International Forum was to provide up to date information on what is happening in blood component therapy and related areas, focussing on new perspectives on component preparation, quality/safety and transfusion reactions. As background information on the state of the art of leucodepletion, I provided an overview of what we learned from universal leucodepletion. Dr. Gracida de Sousa, Portugal focussed on the progress made in leucodepletion, including the potential for filtration––induced granulocyte activation and changes in the subpopulation of leucocytes, as well as highlighting the Lisbon position on HLA activities. Dr. Solheim from Norway provided an article on
improved presentation of coagulation factors after prestorage leukocyte depletion of whole blood and Dr. Oystein Flesland discussed the issue of chimersim. On the session related to new development, Dr. Hans Guillikson, Sweden highlighted new information on buffy coat––derived platelet concentrates, using the Gambro Orbisac. Dr. Eugenia Vasconcelos, Portugal reported on a large scale comparative analysis on the quality monitoring of three types of available platelet concentrates in terms of their functional integrity and aggregation state, using a simple and practical test known as a ‘‘Holly Grail’’ of platelet function testing. For the sake of completeness I have added two short reports related to changes in the haemostatic function of platelet during storage: first changes in the levels of platelet-derived FXIIIA, vWF, Annexin V, Glycocalicin and in the platelet functional integrity during 5–7 days storage. Secondly the use of a new method for monitoring the platelet microvesicle pro-/anti-coagulant activities. On the clinical side, the role of apoptotic cells and TGFB in immunomodulation was discussed masterfully by Prof. Sunny Dzick, USA. Finally, various critical matters related to transfusion complications and how to reduced them was reviewed by Dr. Katheleen Sazama, USA. We received excellent feed back from participants for this exciting programme.
1473-0502/03/$ - see front matter Ó 2003 Elsevier Ltd. All rights reserved. doi:10.1016/S1473-0502(03)00090-9
4
J. Seghatchian / Transfusion and Apheresis Science 29 (2003) 3–4
I am grateful to our international speakers who accepted my invitation to attend and express their views on what we need to know in their specialised fields and to Dr. Gail Rock for agreeing to publish the short summary of this international forum, making the received presentations available to all interested groups.
Jerard Seghatchian Blood Component Technology & Thrombosis/Haemostasis Consultancy 50 Primrose Hill Road London NW3 3AA, UK Tel./fax: +44-207-722-9596 E-mail address: [email protected]
International forum: UK––Part 1
New perspectives on blood components preparation, quality, safety and review of non-viral transfusion complications
The issue of quality improvement of blood components continues to attract much attention from transfusion specialists and clinicians. This is understandable as despite the conceptual acceptance that purer is better and the implementation of this concept to blood component therapy, the potential risk of non-viral adverse reactions is still too high. It is therefore crucial to carefully assess the benefits and shortcomings attributable to various existing blood component technologies, in particular the universal leucodepletion program and put in place continual interventional programs with the aim of improving the safety/efficacy of various products for clinical use. The major goal of this International Forum was to provide up to date information on what is happening in blood component therapy and related areas, focussing on new perspectives on component preparation, quality/safety and transfusion reactions. As background information on the state of the art of leucodepletion, I provided an overview of what we learned from universal leucodepletion. Dr. Gracida de Sousa, Portugal focussed on the progress made in leucodepletion, including the potential for filtration––induced granulocyte activation and changes in the subpopulation of leucocytes, as well as highlighting the Lisbon position on HLA activities. Dr. Solheim from Norway provided an article on
improved presentation of coagulation factors after prestorage leukocyte depletion of whole blood and Dr. Oystein Flesland discussed the issue of chimersim. On the session related to new development, Dr. Hans Guillikson, Sweden highlighted new information on buffy coat––derived platelet concentrates, using the Gambro Orbisac. Dr. Eugenia Vasconcelos, Portugal reported on a large scale comparative analysis on the quality monitoring of three types of available platelet concentrates in terms of their functional integrity and aggregation state, using a simple and practical test known as a ‘‘Holly Grail’’ of platelet function testing. For the sake of completeness I have added two short reports related to changes in the haemostatic function of platelet during storage: first changes in the levels of platelet-derived FXIIIA, vWF, Annexin V, Glycocalicin and in the platelet functional integrity during 5–7 days storage. Secondly the use of a new method for monitoring the platelet microvesicle pro-/anti-coagulant activities. On the clinical side, the role of apoptotic cells and TGFB in immunomodulation was discussed masterfully by Prof. Sunny Dzick, USA. Finally, various critical matters related to transfusion complications and how to reduced them was reviewed by Dr. Katheleen Sazama, USA. We received excellent feed back from participants for this exciting programme.
1473-0502/03/$ - see front matter Ó 2003 Elsevier Ltd. All rights reserved. doi:10.1016/S1473-0502(03)00090-9
4
J. Seghatchian / Transfusion and Apheresis Science 29 (2003) 3–4
I am grateful to our international speakers who accepted my invitation to attend and express their views on what we need to know in their specialised fields and to Dr. Gail Rock for agreeing to publish the short summary of this international forum, making the received presentations available to all interested groups.
Jerard Seghatchian Blood Component Technology & Thrombosis/Haemostasis Consultancy 50 Primrose Hill Road London NW3 3AA, UK Tel./fax: +44-207-722-9596 E-mail address: [email protected]